12 results
8-K
EX-99.1
NEXI
Neximmune Inc
17 Mar 22
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
4:15pm
with the potential to address immune escape mechanisms.”
“NexImmune’s AIM platform has shown itself to be a powerful and novel technology for the activation
10-K
2020 FY
NEXI
Neximmune Inc
31 Mar 21
Annual report
4:02pm
under immune pressure, such as from the CAR T cell. As a result, the tumor cell can avoid detection by the CAR T cell in a process known as tumor escape … can relapse.
NEXI-002 was designed to address these emerging limitations of CAR T therapy.
Tumor escape. Each infusion of NEXI-002 contains
424B4
NEXI
Neximmune Inc
16 Feb 21
Prospectus supplement with pricing info
4:38pm
blasts escape the bone marrow and travel to a ‘sanctuary site’, forming a sarcoma, or solid tumor-like mass. He also failed several targeted therapies … known as tumor escape. We also believe that a primary driver of tumor relapse following CAR T therapy is the loss of CAR T cells from a patient’s body
S-1/A
i5t19it2v9rjz8ja5cbe
8 Feb 21
IPO registration (amended)
7:29am
S-1
EX-10.12
posuadsqip3
19 Jan 21
IPO registration
4:38pm
S-1
9y1378x vbk
19 Jan 21
IPO registration
4:38pm
DRS/A
6haqwxw
15 Jan 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.12
1ws4xl
15 Jan 21
Draft registration statement (amended)
12:00am
DRS
qhs7q 9dtaph8k7os
14 Dec 20
Draft registration statement
12:00am
- Prev
- 1
- Next